73792-08-2

Usage

Uses

Used in Pharmaceutical Synthesis:
METHYL 4-AMINO-2-FLUOROBENZOATE is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with specific therapeutic properties.
Used in Agrochemical Production:
In the agrochemical industry, METHYL 4-AMINO-2-FLUOROBENZOATE is utilized as an intermediate, playing a crucial role in the creation of compounds that can protect crops and enhance agricultural productivity.
Used in Organic Chemistry:
METHYL 4-AMINO-2-FLUOROBENZOATE is employed as a reagent in organic chemistry for the preparation of other compounds, highlighting its importance in the synthesis of a wide range of chemical entities.
Used in Antifungal Applications:
METHYL 4-AMINO-2-FLUOROBENZOATE has been studied for its potential biological activities, particularly as an antifungal agent, which could be beneficial in treating fungal infections or in the development of antifungal products.

InChI:InChI=1/C8H8FNO2/c1-12-8(11)6-3-2-5(10)4-7(6)9/h2-4H,10H2,1H3

Upstream product

• 392-09-6 2-fluoro-4-nitro-benzoic acid methyl ester 
• 125568-77-6 methyl 4-azido-2-fluorobenzoate 
• 109-89-7 diethylamine 
• 108-88-3 toluene 
• 67-56-1 methanol 
• 446-31-1 2-fluoro-4-aminobenzoic acid 
• 403-24-7 2-fluoro-4-nitrobenzoic acid 
• 1427-07-2 2-fluoro-4-nitrotoluene 

Downstream Products

• 125568-77-6 methyl 4-azido-2-fluorobenzoate 
• 125568-83-4 methyl N-benzyl-4-amino-2-fluorobenzoate 
• 73792-09-3 2-Fluoro-4-hexadecylamino-benzoic acid methyl ester 
• 959778-24-6 methyl 2-fluoro-4-{[(2-fluorophenyl)carbonyl]amino}benzoate 
• 232950-90-2 5-(S)-Acetamidomethyl-3-[4'-formyl-3'-fluorophenyl]oxazolidine-2-one 
• 840501-16-8 (3-fluoro-4-hydroxymethyl-phenyl)-carbamic acid benzyl ester 
• 840501-17-9 [4-(tert-butyl-dimethyl-silanyloxymethyl)-3-fluoro-phenyl]-carbamic acid benzyl ester 
• 660432-46-2 2-fluoro-4-methylamino benzoic acid methyl ester 
• 1402582-08-4 4-(3-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)ureido)-2-fluorobenzoic acid 
• 1402582-03-9 4-[[[2-(3-chlorophenyl)-5-(trifluoromethyl)-2H-pyrazol-3-yl]methylcarbamoyl]amino]-2-fluoro-N,N-dimethylbenzamide 
• 1402582-04-0 4-[[[2-(3-chlorophenyl)-5-(trifluoromethyl)-2H-pyrazol-3-yl]methylcarbamoyl]amino]-2-fluoro-N-(2-hydroxyethyl)benzamide 
• 1402582-01-7 4-[[[2-(3-chlorophenyl)-5-(trifluoromethyl)-2H-pyrazol-3-yl]methylcarbamoyl]amino]-2-fluorobenzamide 
• 1402586-48-4 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)-2H-pyrazol-3-yl]-methyl]-3-[3-fluoro-4-(methoxycarbonyl)-phenyl]-urea 
• 1582286-22-3 4-acetamido-2-fluoro-N-methoxy-N-methylbenzamide 

Relevant academic research and scientific papers

DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST

The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.

INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR

The present application discloses an indole as represented by formula (I) used as a CRTH2 inhibitor, and a pharmaceutically acceptable salt or tautomer of the indole, and an application of same in treating a disease related to a CRTH2 receptor.

Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist

A ligand-based virtual screening exercise examining likely bioactive conformations of AM 580 (2) and AGN 193836 (3) was used to identify the novel, less lipophilic RARα agonist 4-(3,5-dichloro-4-ethoxybenzamido)benzoic acid 5, which has good selectivity over the RARβ and RARγ receptors. Analysis of the medicinal chemistry parameters of the 3,5-substituents of derivatives of template 5 enabled us to design a class of drug-like molecules with lower intrinsic clearance and higher oral bioavailability which led to the novel RARα agonist 4-(3-chloro-4-ethoxy-5-isopropoxybenzamido)-2-methylbenzoic acid 56 that has high RARα potency and excellent selectivity versus RARβ (2 orders of magnitude) and RARγ (4 orders of magnitude) at both the human and mouse RAR receptors with improved drug-like properties. This RARα specific agonist 56 has high oral bioavailability (>80%) in both mice and dogs with a good PK profile and was shown to be inactive in cytotoxicity and genotoxicity screens.

Compound and composition as well as application thereof to drugs preparation

The present invention relates to a compound having a structure of formula I or a pharmaceutically acceptable salt of the compound. Regarding the compound, R1 is selected from hydrogen, fluorine, and chlorine; R2 and R3 are independently selected from hydr

Mechanistic Evaluation of Bioorthogonal Decaging with trans-Cyclooctene: The Effect of Fluorine Substituents on Aryl Azide Reactivity and Decaging from the 1,2,3-Triazoline

Bioorthogonal prodrug activation/decaging strategies need to be selective, rapid and release the drug from the masking group upon activation. The rates of the 1,3-dipolar cycloaddition between a trans-cyclooctene (TCO) and a series of fluorine-substituted

As CRTH2 inhibitor of indole compounds (by machine translation)

The application discloses a formula (I) as shown in CRTH2 inhibitor of indole compound or its pharmaceutically acceptable salt, and their use in the treatment with the CRTH2 receptor-related diseases in the application. (by machine translation)

THIAZOLIDINONE COMPOUNDS AND USE THEREOF

A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH A CO-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a CO-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

THERAPEUTIC ARYL-AM I DO-ARYL COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as "AAA compounds"), which, inter alia, a

The design and optimization of a series of 2-(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators

The optimization of a series of benzimidazole glucokinase activators is described. We identified a novel and potent achiral benzimidazole derivative as an allosteric GK activator. This activator was designed and synthesized via removal of the chiral center of the lead compound, 6-(N-acylpyrrolidin-2-yl)benzimidazole. The activator exhibited good PK profiles in rats and dogs, and significant hypoglycemic efficacy at 1 mg/kg po dosing in a rat OGTT model. The binding site and binding mode of the benzimidazole class of GKA with GK protein was confirmed by X-ray crystallographic analysis.